

Closing

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

GE HEALTHCARE LIMITED,
MEDI-PHYSICS INC., DBA GE
HEALTHCARE,

Plaintiffs,

v.

JUBILANT DRAXIMAGE INC.,
D.B.A. JUBILANT RADIOPHARMA,

Defendant.

Civil Action No.: 2:24-cv-06486-
MCA-SDA

(Filed Electronically)

CONSENT JUDGMENT

GE Healthcare Limited (“GEHC Ltd.”) and Medi-Physics Inc., dba GE HealthCare (“Medi-Physics”) (collectively, “Plaintiffs”) and Jubilant DraxImage Inc., d.b.a. Jubilant Radiopharma (“Jubilant”), the parties in the above-captioned action, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the action, as follows:

IT IS this 13 day of Feb, 2025:

ORDERED, ADJUDGED AND DECREED as follows:

1. This District Court has jurisdiction over the subject matter of the above-captioned action and has personal jurisdiction over the parties.

2. As used in this Consent Judgment, (i) the term “Jubilant ANDA Product” shall mean the drug product made, sold, offered for sale, imported, or distributed pursuant to Abbreviated New Drug Application (“ANDA”) No. 217224 (“the Jubilant ANDA”); (ii) the term “Approved MYOVIEW™ 30mL Product” shall mean any product made, sold, offered for sale, imported, or distributed pursuant to NDA No. 20372; (iii) the term “Licensed Patent” shall mean U.S. Patent No. 9,549,999; and (iv) the term “Affiliate” shall mean any entity or person that directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Jubilant. For purposes of this definition, “control” means the direct or indirect ownership of at least fifty percent (50%) of such entity’s capital or equivalent voting rights.

3. Unless otherwise specifically authorized, Jubilant and its Affiliates, successors, and assigns are enjoined from infringing the Licensed Patent by making, having made, using, selling, offering to sell, importing, or distributing the Jubilant ANDA Product.

4. Compliance with this Consent Judgment may be enforced by Plaintiffs and their successors in interest, or assigns.

5. The District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and any related agreements.

6. All claims and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.

7. For the avoidance of doubt, nothing in this Consent Judgment prohibits Jubilant or its Affiliates from filing or maintaining with the FDA a "Paragraph IV Certification" for the Jubilant ANDA Product pursuant to 21 U.S.C. § 355(j)(2)(vii)(IV) with respect to the Licensed Patent or any other patent which may be listed in the FDA Orange Book in connection with the Approved MYOVIEW™ 30mL Product solely for the purposes of receiving or maintaining final approval of the Jubilant ANDA Product.

8. Nothing herein shall prevent FDA from granting final approval of the Jubilant ANDA.



Judge Madeline Cox Arleo

We hereby consent to the form and entry of this Order:

By: s/Douglas R. Weider

Douglas R. Weider
James L. Ryerson
GREENBERG TRAURIG LLP
500 Campus Drive Suite 400
Florham Park, NJ 07932
(973) 360-7900

By: s/Ian Scott

Ian Scott (admitted in NJ)
Stephen R. Auten
Luke T. Shannon
Taft, Stettinius & Hollister LLP
111 East Wacker
Suite 2600

weiderd@gtlaw.com
ryersonj@gtlaw.com

Jeffrey P. Kushan
Lauren Cranford Katzeff
SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, D.C. 20005
(202) 736-8000
jkushan@sidley.com
lkatzeff@sidley.com

Stephanie P. Koh
Rachel B. Zingg
SIDLEY AUSTIN LLP
One South Dearborn St.
Chicago, IL 60603
(312) 853-7000
skoh@sidley.com
rzingg@sidley.com

*Attorneys for Plaintiffs GE
Healthcare Limited and Medi-
Physics Inc., dba GE HealthCare*

Chicago, IL 60601
iscott@taftlaw.com
sauten@taftlaw.com
lshannon@taftlaw.com

*Attorneys for Defendant Jubilant
DraxImage Inc. d.b.a. Jubilant
Radiopharma*